Difference between calculated and direct-measured low-density lipoprotein cholesterol in subjects with diabetes mellitus or taking lipid-lowering medications

被引:14
|
作者
Choi, Su-Yeon [2 ]
Park, Hyo Eun [2 ]
Kim, Min-Kyung [2 ]
Shin, Chan Soo [2 ]
Cho, Sang-Heon [2 ]
Oh, Byung-Hee [1 ]
机构
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Healthcare Syst Gangnam Ctr, Seoul 135984, South Korea
关键词
Low-density lipoprotein cholesterol; Friedewald formula; Diabetes mellitus; Triglyceride; Community-based study; CORONARY-HEART-DISEASE; ASSAY; RISK;
D O I
10.1016/j.jacl.2011.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: We evaluated factors that caused differences between calculated low-density lipoprotein cholesterol (C-LDL-C) and direct-measured LDL-C (D-LDL-C) and compared them in subjects with diabetes mellitus (DM) or taking lipid-lowering medications. METHODS: 21,452 subjects (9,177 women, 12,275 men; 8.1% with DM and 8.5% on lipid-lowering medications) were included in the analysis. Participants were classified into 3 groups, i.e., group 1: the subjects without DM and not on lipid-modifying drugs (n = 18,287), group 2: without DM and on lipid-modifying drugs (n = 1,423), and group 3: with DM (n = 1,742). LDL-C concentrations were either directly measured by a homogenous method or calculated by Friedewald formula. RESULTS: There was a significant correlation between C-LDL-C and D-LDL-C (r = 0.966, P < .001). The absolute values of the differences between two LDL-C values were 7.0 +/- 6.2 mg/dl and 6.6 +/- 7.3% (6.6 +/- 5.9 mg/dl and 6.0 +/- 6.5%, 8.8 +/- 6.7 mg/dl and 9.1 +/- 9.7%, and 10.1 +/- 7.3 mg/dl and 10.7 +/- 10.1% in group 1, 2, and 3 respectively, P < .001). The subjects with the absolute value of the differences of LDL-C >= 10% was 20.2% (17.3%, 31.3%, and 41.1% in group 1, 2, and 3 respectively, P < .001). In the multiple logistic regression analysis, high triglyceride (>= 150 mg/dl), low high-density lipoprotein cholesterol (HDL-C) (<40 mg/dl), male gender, obesity (body mass index >= 25 kg/m(2)), DM and taking lipid-lowering drugs were significant associated with high LDL-differences (the absolute value of the differences >= 10% or >= 10 mg/dl). CONCLUSION: D-LDL-C was generally higher by 5 mg/dl or 5% than C-LDL-C. The differences C-LDL-C and D-LDL-C were higher in subjects with DM and on lipid-lowering medications. Male gender, high triglyceride, low HDL-C, and obesity were also associated with the greater differences between C-LDL-C and D-LDL-C. (C) 2012 National Lipid Association. All rights reserved.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 50 条
  • [41] The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies:: relationship with low-density lipoprotein oxidation and plasma total antioxidant status
    Örem, C
    Örem, A
    Uydu, HA
    Çelik, S
    Erdöl, C
    Kural, BV
    CORONARY ARTERY DISEASE, 2002, 13 (01) : 65 - 71
  • [42] Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus
    Saag, Jordan L.
    Gross, Dennis
    Stirt, Daniel
    Rey, Andrea Espina
    Gros, Bernard
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [43] ASSOCIATION BETWEEN SIZE OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL PARTICLES AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES SUBJECTS
    Lo Coco, G.
    Molina, J. Sanz
    Luciani, F.
    Semprini, C. M.
    Dalla Nora, E.
    Zuliani, G.
    Vigna, G. B.
    Passaro, A.
    ATHEROSCLEROSIS, 2020, 315 : E201 - E201
  • [44] Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome
    Huilian Tan
    Ling Liu
    Qinghou Zheng
    Dahong Zhang
    Qian Liu
    Dong Cui
    Lei Gao
    Zhen Wang
    Wen-Lei Wang
    Jun Liu
    Advances in Therapy, 2021, 38 : 3389 - 3398
  • [45] A Contemporary Assessment of Lipid Lowering Therapies and Low-density Lipoprotein Cholesterol in Peripheral Artery Disease
    Hess, Connie N.
    Cannon, Christopher P.
    Beckman, Joshua A.
    Goodney, Philip
    Patel, Manesh R.
    Shannon, Erin
    Orroth, Kate K.
    Mues, Katherine E.
    Hiatt, William R.
    Bonaca, Marc P.
    CIRCULATION, 2020, 142
  • [46] Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome
    Tan, Huilian
    Liu, Ling
    Zheng, Qinghou
    Zhang, Dahong
    Liu, Qian
    Cui, Dong
    Gao, Lei
    Wang, Zhen
    Wang, Wen-Lei
    Liu, Jun
    ADVANCES IN THERAPY, 2021, 38 (06) : 3389 - 3398
  • [47] Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project
    Landmesser, Ulf
    Pirillo, Angela
    Farnier, Michel
    Jukema, J. Wouter
    Laufs, Ulrich
    Mach, Francois
    Masana, Luis
    Pedersen, Terje R.
    Schiele, Francois
    Steg, Gabriel
    Tubaro, Marco
    Zaman, Azfar
    Zamorano, Pepe
    Catapano, Alberico L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2020, 42 : E49 - E58
  • [48] Impact of an Intensive Lipid-Lowering Therapy Protocol on Achieving Target Low-Density Lipoprotein Cholesterol Levels in Patients With Acute Coronary Syndrome
    Seiyama, Kosuke
    Oka, Akihiro
    Miyoshi, Toru
    Sudo, Yuya
    Takagi, Wataru
    Ugawa, Satoko
    Okada, Tomoaki
    Nosaka, Kazumasa
    Doi, Masayuki
    CIRCULATION REPORTS, 2025, 7 (02) : 131 - 138
  • [49] LIPID-LOWERING THERAPY PATTERNS AND LOW-DENSITY LIPOPROTEIN-CHOLESTEROL MANAGEMENT AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN ALBERTA, CANADA
    Scory, Tayler
    Chen, Guanmin
    Farris, Megan S.
    Shih, Yu-Hsuan
    Pinto, Lionel
    Cowling, Tara
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 44 - 44
  • [50] Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study
    Bouillon, Kim
    Singh-Manoux, Archana
    Jokela, Markus
    Shipley, Martin J.
    Batty, G. David
    Brunner, Eric J.
    Sabia, Severine
    Tabak, Adam G.
    Akbaraly, Tasnime
    Ferrie, Jane E.
    Kivimaki, Mika
    HEART, 2011, 97 (11) : 923 - 930